2018
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial
Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, Virata M, Brown ST, Justice AC, Bryant KJ, Fiellin DA, Fiellin LE. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. AIDS And Behavior 2018, 23: 211-221. PMID: 30073637, PMCID: PMC6476298, DOI: 10.1007/s10461-018-2241-z.Peer-Reviewed Original ResearchConceptsHIV-positive patientsHeavy drinking daysVACS Index scoreXR-NTXART adherenceDrinking daysIndex scoreUndetectable HIV viral loadCD4 cell countExtended-release naltrexoneDouble-blind placeboHIV viral loadRandomized-controlled trialDrinking outcomesHIV biomarkersSecondary outcomesHIV outcomesPrimary outcomeViral loadAntiretroviral adherenceClinical trialsCell countAlcohol treatmentHIVPatients
2017
2432
Huang Y, Brown S, Ma S, Kyriakides T. 2432. Journal Of Clinical And Translational Science 2017, 1: 37-37. PMCID: PMC6799711, DOI: 10.1017/cts.2017.137.Peer-Reviewed Original ResearchAdvanced HIV diseaseARV medicationsHIV diseaseVirtual phenotypeSubsequent managementARV treatment strategiesEffects of ARVHIV treatment trialsIndividual ARV drugsCD4 cell countAnti-retroviral drugsCurrent clinical practiceOpen labelSpecific ARVsStandard armARV regimenIntensive armViral loadTherapeutic optionsVital statusARV drugsTreatment trialsARV treatmentTreatment strategiesTrial randomizationIntegrated Tuberculosis/Human Immunodeficiency Virus Community-Based Case Finding in Rural South Africa: Implications for Tuberculosis Control Efforts
Shenoi SV, Moll AP, Brooks RP, Kyriakides T, Andrews L, Kompala T, Upadhya D, Altice FL, Eksteen FJ, Friedland G. Integrated Tuberculosis/Human Immunodeficiency Virus Community-Based Case Finding in Rural South Africa: Implications for Tuberculosis Control Efforts. Open Forum Infectious Diseases 2017, 4: ofx092. PMID: 28695145, PMCID: PMC5499582, DOI: 10.1093/ofid/ofx092.Peer-Reviewed Original ResearchHuman immunodeficiency virusIntensive case findingCase findingResistant TBTB casesHIV testingRural South AfricaOverall case notification rateConcurrent HIV testingHIV coinfection rateHIV-negative tuberculosisMedian CD4 countCD4 cell countHIV/TBDrug-resistant TBCase notification ratesCase-finding strategyHIV-positive individualsHigh-risk populationTB symptom screeningPopulation-level ratesCD4 countTuberculosis symptomsSymptom screeningTB elimination
2015
Trends in hospital deaths among human immunodeficiency virus–infected patients during the antiretroviral therapy era, 1995 to 2011
Cowell A, Shenoi SV, Kyriakides TC, Friedland G, Barakat LA. Trends in hospital deaths among human immunodeficiency virus–infected patients during the antiretroviral therapy era, 1995 to 2011. Journal Of Hospital Medicine 2015, 10: 608-614. PMID: 26130520, PMCID: PMC4560992, DOI: 10.1002/jhm.2409.Peer-Reviewed Original ResearchConceptsHospital deathAIDS deathsHuman immunodeficiency virus-infected patientsHigher CD4 cell countsAIDS infectionAntiretroviral therapy eraNon-AIDS deathsNon-AIDS malignanciesCD4 cell countHIV viral loadVirus-infected patientsHuman immunodeficiency virusUrban teaching hospitalTimes greater likelihoodCardiovascular comorbiditiesTherapy eraCD4 countInpatient mortalityImmunodeficiency syndromeLiver diseaseUnderlying liverViral loadImmunodeficiency virusMedical recordsAntiretroviral era
2012
Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients
Bedimo R, Kyriakides T, Brown S, Weidler J, Lie Y, Coakley E, Holodniy M. Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients. HIV Medicine 2012, 13: 345-351. PMID: 22276745, DOI: 10.1111/j.1468-1293.2011.00981.x.Peer-Reviewed Original ResearchConceptsCD4 cell countViral load changesWeek 12Replication capacityPredictive valueCell countCD4 cell count responseHIV-1 replication capacityAntiretroviral treatment responseHIV replication capacityImmediate salvage therapyPhenotypic susceptibility scoresDrug-free periodPhenotypic resistance testingCell count responseAdditional predictive valueMultivariate regression analysisTreatment reinitiationSalvage therapyWeek 24ARV therapyViral loadPrognostic valueARV treatmentAntiretroviral trials
2009
Health-Related Quality of Life in a Randomized Trial of Antiretroviral Therapy for Advanced HIV Disease
Joyce VR, Barnett PG, Bayoumi AM, Griffin SC, Kyriakides TC, Yu W, Sundaram V, Holodniy M, Brown ST, Cameron W, Youle M, Sculpher M, Anis AH, Owens DK. Health-Related Quality of Life in a Randomized Trial of Antiretroviral Therapy for Advanced HIV Disease. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 50: 27-36. PMID: 19295332, DOI: 10.1097/qai.0b013e31818ce6f3.Peer-Reviewed Original ResearchConceptsHealth Utilities Index Mark 3Treatment-experienced HIV patientsEQ-5DHIV patientsHRQoL scoresClinical variablesMedical Outcomes Study HIV Health SurveyEQ-5D visual analog scaleHealth statusStandard gamblePreference-based health-related qualityAdvanced HIV diseaseBaseline HRQOL scoresConcomitant medication useTreatment-experienced HIVCD4 cell countHIV viral loadHealth-related qualityVisual analog scaleVeterans Affairs hospitalEQ-5D VASCross-sectional studyPreference-based HRQOLQuality of lifeTime trade-off (TTO) technique